三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
图表31国内靶向KRAS-G12C二线NSCLC治疗竞争格局及临床数据对比(非头对头)
图表31国内靶向KRAS-G12C二线NSCLC治疗竞争格局及临床数据对比(非头对头)
竞争格局
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:344KB
图片尺寸:2302*990
同报告图片
/
4
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
所属报告:
中国生物制药-港股公司研究报告:百亿单品可期四大板块并进创新+国际化双轮驱动-241008(31页).pdf
打包全文图表
相关数据
ADC联合IO单抗治疗一线NSCLC全球三期研究启动时间
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
收藏
行业数据
2026-07-14
原图定位
查看详情
KRASG12C一线治疗NSCLC竞争格局(截至2026-6-25)
收藏
竞争格局
2026-07-01
原图定位
查看详情
全球KRASG12C突变的NSCLC发病人数
收藏
行业数据
2026-07-01
原图定位
查看详情
中国KRASG12C突变的NSCLC发病人数
收藏
行业数据
2026-07-01
原图定位
查看详情
SHR-A2009用于EGFR突变型NSCLC的1期临床研究结果
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
收藏
行业数据
2026-05-28
原图定位
查看详情
SHR-A2009用于一线NSCLC患者的研究结果
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
收藏
行业数据
2026-05-28
原图定位
查看详情
PD(L)1*VEGF双抗单药针对一线NSCLC数据汇总
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
收藏
行业数据
2026-03-13
原图定位
查看详情
各药物针对IO耐药NSCLC临床数据汇总
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
收藏
行业数据
2026-03-13
原图定位
查看详情
驱动基因阴性晚期NSCLC治疗格局
收藏
竞争格局
2026-02-24
原图定位
查看详情
NSCLC1L全球竞争格局AK112BNT327707
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
收藏
竞争格局
2026-01-28
原图定位
查看详情
全球范围内目前已上市的5款KRAS抑制剂
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
收藏
行业数据
2026-01-07
原图定位
查看详情
KRAS(OFF)抑制剂机理
fCDnu4TliIYv6L+H56iLICAgICAgICAgIHwg5o+P6L+wICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwtLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCDnlJ/plb/lm6DlrZAgICAgICAgICAgICB8IOe7k+WQiFJUS++8jOWQr+WKqOS/oeWPt+S8oOWvvCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCBSVEsgICAgICAgICAgICAgICAgIHwg5Y+X5L2T6YWq5rCo6YW45r+A6YW277yM6KKr55Sf6ZW/5Zug5a2Q5r+A5rS75ZCO56O36YW45YyWICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCBHUkIy44CBU0hQMuOAgVNPUyAgICAgfCDmjqXlpLTom4vnmb3lj4pHRUbvvIzlj4LkuI5LUkFT55qE5rS75YyWICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCBLUkFTIChHRFAtYm91bmQpICAgIHwg4oCcb2ZmIHN0YXRl4oCd77yM5oqR5Yi25YmC57uT5ZCI5ZCO6ZSB5a6a5q2k54q25oCBICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCBLUkFTIChHVFAtYm91bmQpICAgIHwg5rS75oCn54q25oCB77yM5Y+v5r+A5rS75LiL5ri4UkFG5ZKMUEkzSyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgUkFG4oaSTUVL4oaSRVJLICAgICAgICAgfCBNQVBL6YCa6Lev77yM5L+D6L+b57uG6IOe5a2Y5rS7ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgUEkzS+KGkkFLVOKGkm1UT1IgICAgICAgfCBQSTNLIC0gQUtUIC0gbVRPUumAmui3r++8jOiwg+aOp+e7huiDnueUn+WtmOS4juWinuauliAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgS1JBUyAoT0ZGKSBJbmhpYml0b3JzIHwg57uT5ZCI5bm26ZSB5a6aS1JBU+iHs0dEUCAtIGJvdW5kIOKAnG9mZiBzdGF0ZeKAne+8jOaKkeWItuS/oeWPt+S8oOWvvCAgICAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77yaQmlvUGx1c++8jEFTQ0/vvIzljY7ph5Hor4HliLjnoJTnqbbmiYA=
收藏
行业数据
2026-01-07
原图定位
查看详情
KRAS(ON)抑制剂机理
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
收藏
行业数据
2026-01-07
原图定位
查看详情
KRAS(ON/OFF)抑制剂机理
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
收藏
行业数据
2026-01-07
原图定位
查看详情
SI-B001针对PD-(L1)抑制剂治疗失败的野生型NSCLC的mPFS数据
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
收藏
行业数据
2025-12-26
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
KRAS-G12C抑制剂格舒瑞昔研发进度和临床数据具备竞争优势。目前信达生物/劲方医药的福泽雷塞已于 2024年 8 月获CDE 批准上市,用于 KRAS-G12C突变的二线 NSCLC治疗。此外,国内 2款 KRAS-G12C抑制剂处于 NDA 阶段,分别为加科思的格来雷塞、正大天晴/益方生物的格舒瑞昔。从化学结构看,格舒瑞昔相比索拖拉西布,结构改造后分子空间构象进一步优化,靶点结合效果更佳。根据 2024年WCLC数据,2024年 5月,格舒瑞昔治疗肺癌 II期单臂临床结果显示,在携带 KRAS-G12C突变的二线 NSCLC患者中,格舒瑞昔的客观缓解率(ORR)为 52.0%,疾病控制率(DCR)为 88.6%,中位缓解持续时间(DOR)为 12.5个月,中位无进展生存期(PFS)为 9.1个月,中位OS尚未达到(估计为 14.1个月),显示出较高的肿瘤缓解率和较长的缓解持续时间,安全性方面也显示出良好的耐受性和可控性。而美国已上市产品索拖拉西布和阿达格拉西ORR分别为 37.1%和 42.9%,PFS分别为 6.3和 6.5个月,目前均处于国内临床 III期,格舒瑞昔在研发进度和临床数据均具备竞争优势。
竞争格局
原图定位
当前图表所属:
中国生物制药-港股公司研究报告:百亿单品可期四大板块并进创新+国际化双轮驱动-241008(31页).pdf
图表92023年同类可比公司销售人员数量对比(人)
图表82018-2024H1公司期间费用率(%)
图表72018-2024H1公司销售毛利率和持续经营业务
图表6中国生物制药2018-2024H1经调归母净利润及
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》